Valeant Posts First Quarter Net Loss but Revenues Jump 77%

Thu, 05/08/2014 - 8:10am
The Canadian Press

LAVAL, Que. - Valeant Pharmaceuticals International reports a first-quarter net loss of $23 million, but says its revenues jumped 77 per cent to $1.9 billion.

The Quebec-based company says it had a loss of seven cents per diluted share, compared with a loss of $27.5 million, or nine cents per share, in the same quarter of 2013.

Valeant says the loss includes restructuring, integration and other charges of $135 million primarily related to the acquisition of eyecare company Bausch + Lomb last year.

Revenues jumped 77 per cent to $1.9 billion, up from $1.06 billion year-over-year.

Valeant says on a cash earnings per share basis, adjusted income was $600 million or $1.76 per diluted share, an increase of 35 per cent over the prior year.

The company recently made a hostile offer for Botox maker Allergan.

Valeant has said its goal is to be one the world's top five pharmaceutical companies, with a market value of roughly $150 billion.

It was originally based in California and merged with Canada's Biovail in 2010, headquartered in Mississauga, Ont. Valeant moved its global headquarters to Laval, near Montreal, in 2012.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.